TrialJournal of translational medicine2026

Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations.

Yutong Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.